Disease characteristics of patients with SSc
| SSc phenotype | Patients with SSc, n=74 |
| Age, median (IQR) | 57 (49, 63) |
| Female | 63 (85) |
| Disease subtype | |
| lcSSc | 50 (68) |
| dcSSc | 24 (32) |
| Disease duration (years), median (IQR) | 8 (2, 16) |
| History of | |
| Digital ulceration | 16 (22) |
| Calcinosis | 17 (23) |
| Myositis | 3 (4) |
| GORD | 66 (90) |
| Interstitial lung disease | 29 (39) |
| Current use of DMARD | 42 (57) |
| Clinical profile | |
| Total modified Rodnan skin score, median (IQR) | 2 (1, 6) |
| Digital ulceration | 10 (14) |
| Tendon friction rubs | 2 (3) |
| Calcinosis | 14 (19) |
| Antibody profile | |
| ANA | 69 (93) |
| ACA | 27 (36) |
| Scl70 | 22 (30) |
| CV risk factors | |
| Any CV risk factors, | 21 (28) |
| FHx premature CVD | 8 (11) |
| Smoking | 6 (8) |
| Dyslipidaemia | 3 (4) |
| HBP | 8 (11) |
| One CV risk factor | 16 (21) |
| Two CV risk factors | 5 (7) |
N % presented unless stated otherwise.
ACA, anti-centromere antibody; ANA, antinuclear antibodies; CV, cardiovascular; CVD, cardiovascular disease; dcSSc, diffuse cutaneous systemic sclerosis; DMARD, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; FHx, family history; GORD, gastro-oesophageal reflux disease; HBP, high blood pressure; lcSSc, limited cutaneous systemic sclerosis; Scl70, anti-topoisomerase antibody; SSc, systemic sclerosis.